Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Nov 4;9:116. doi: 10.3389/fnmol.2016.00116

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Jackson, Dayton, Deverman and Klein.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

AAV-PHP.B provides increased transduction efficiency in the CNS relative to AAV9. Neonatal rats were injected intravenously with the CBA promoter construct packaged into either AAV9 or AAV-PHP.B under equal conditions, with a 4 week expression interval. (A,B) There was stronger GFP expression in the cerebella of rats administered AAV-PHP.B. (C–F) The same pattern was found in the spinal cord (C,D) and the heart (E,F). (G,H) Interestingly, AAV-PHP.B did not appear to similarly increase expression in liver, which is consistent with improved neuronal targeting. (I) GFP-positive area in the cerebellum (t-test, p < 0.001, n = 4–5/per AAV capsid serotype group). GFP immunostaining in (A–H). Bar in (A) = 536 μm, same magnification in (B). Bar in (C) = 67 μm, same magnification in (D). Bar in (E) = 134 μm, same magnification in (F–H). *Indicates p < 0.001.